Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4144)	4/25/1998 12:40:00 AM
From: Peter Singleton	of 6136

Steve, you make a good point. Why not ask IR why they didn't issue a press release on either the pivotal PII/PIII 3340 trials, or the selection of a lead compound for rhinovirus protease. My point about good news not helping the stock, and not-so-good news hurting the stock is an observation based on the past 6-7 months. Most times when material good news was released, e.g., the past quarter's earnings, with the pipeline update, the market yawned. But bad news (Roche withdrawal / Thymitaq termination), the market pounded AGPH. It's simply a bearish climate for AGPH, and many other biotechs (but not all). In a bullish climate, good news would tend to get rewarded, and news that raised red flags would tend to be overlooked. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next